(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Leptomeningeal Metastases pipeline constitutes 5+ key companies continuously working towards developing 5+ Leptomeningeal Metastases treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Leptomeningeal Metastases Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.
The Leptomeningeal Metastases Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Leptomeningeal Metastases Pipeline Outlook
Some of the key takeaways from the Leptomeningeal Metastases Pipeline Report:
- Leptomeningeal Metastases Companies across the globe are diligently working toward developing novel Leptomeningeal Metastases treatment therapies with a considerable amount of success over the years.
- Leptomeningeal Metastases companies working in the treatment market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others, are developing therapies for the Leptomeningeal Metastases treatment
- Emerging Leptomeningeal Metastases therapies such as Rhenium-186 NanoLiposome (186RNL), AZD1390, Paclitaxel trevatide (ANG1005), Omburtamab, and others are expected to have a significant impact on the Leptomeningeal Metastases market in the coming years.
- On January 2024, Plus Therapeutics announced results of a Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety, & Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases.
- On April 2023, Angiochem announced results of a Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician’s Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD).
- On March 2022, Kadmon Corporation announced results of A Phase 2, Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases.
Leptomeningeal Metastases Overview
Leptomeningeal metastases (LM), also known as leptomeningeal carcinomatosis, is a severe and advanced complication of cancer where malignant cells spread to the leptomeninges, the two innermost layers of tissue covering the brain and spinal cord. This condition occurs in 5-8% of all cancer patients, with higher incidences in those with cancers of the breast, lung, and melanoma.
Leptomeningeal metastases occurs when cancer cells migrate through the bloodstream or directly invade the cerebrospinal fluid (CSF). These cells can then disseminate throughout the central nervous system (CNS), leading to widespread neurological symptoms. Common Leptomeningeal metastases symptoms include headache, nausea, vomiting, changes in mental status, cranial nerve deficits, back pain, and motor or sensory disturbances.
Diagnosis of Leptomeningeal metastases typically involves imaging studies like MRI, which can reveal abnormalities in the meninges, and lumbar puncture to analyze CSF for malignant cells or elevated protein levels
Treatment options for Leptomeningeal metastases are limited and primarily palliative, focusing on alleviating symptoms and improving quality of life. They include intrathecal chemotherapy (delivered directly into the CSF), systemic chemotherapy, radiation therapy, and corticosteroids to reduce inflammation and pressure. Despite treatment, the prognosis for Leptomeningeal metastases remains poor, with a median survival time of a few months. Early detection and intervention are crucial for managing symptoms and prolonging survival.
Get a Free Sample PDF Report to know more about Leptomeningeal Metastases Pipeline Therapeutic Assessment- Leptomeningeal Metastases Treatment Market
Leptomeningeal Metastases Route of Administration
Leptomeningeal Metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Leptomeningeal Metastases Molecule Type
Leptomeningeal Metastases Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Leptomeningeal Metastases Pipeline Therapeutics Assessment
- Leptomeningeal Metastases Assessment by Product Type
- Leptomeningeal Metastases By Stage and Product Type
- Leptomeningeal Metastases Assessment by Route of Administration
- Leptomeningeal Metastases By Stage and Route of Administration
- Leptomeningeal Metastases Assessment by Molecule Type
- Leptomeningeal Metastases by Stage and Molecule Type
DelveInsight’s Leptomeningeal Metastases Report covers around 5+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Leptomeningeal Metastases product details are provided in the report. Download the Leptomeningeal Metastases pipeline report to learn more about the emerging Leptomeningeal Metastases therapies- Leptomeningeal Metastases Therapeutic Assessment
Leptomeningeal Metastases Pipeline Analysis:
The Leptomeningeal Metastases pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Leptomeningeal Metastases with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leptomeningeal Metastases Treatment.
- Leptomeningeal Metastases key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Leptomeningeal Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leptomeningeal Metastases market.
Download Sample PDF Report to know more about Leptomeningeal Metastases drugs and therapies- Leptomeningeal Metastases Clinical Trials and FDA Approvals
Scope of Leptomeningeal Metastases Pipeline Drug Insight
- Coverage: Global
- Key Leptomeningeal Metastases Companies: Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
- Key Leptomeningeal Metastases Therapies: Rhenium-186 NanoLiposome (186RNL), AZD1390, Paclitaxel trevatide (ANG1005), Omburtamab, and others.
- Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
- Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers
Request for Sample PDF Report for Leptomeningeal Metastases Pipeline Assessment and clinical trials – Leptomeningeal Metastases Drugs and Therapies
Table of Contents
1. Leptomeningeal Metastases Report Introduction
2. Leptomeningeal Metastases Executive Summary
3. Leptomeningeal Metastases Overview
4. Leptomeningeal Metastases- Analytical Perspective In-depth Commercial Assessment
5. Leptomeningeal Metastases Pipeline Therapeutics
6. Leptomeningeal Metastases Late Stage Products (Phase II/III)
7. Leptomeningeal Metastases Mid Stage Products (Phase II)
8. Leptomeningeal Metastases Early Stage Products (Phase I)
9. Leptomeningeal Metastases Preclinical Stage Products
10. Leptomeningeal Metastases Therapeutics Assessment
11. Leptomeningeal Metastases Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Leptomeningeal Metastases Companies
14. Leptomeningeal Metastases Key Products
15. Leptomeningeal Metastases Unmet Needs
16 . Leptomeningeal Metastases Market Drivers and Barriers
17. Leptomeningeal Metastases Future Perspectives and Conclusion
18. Leptomeningeal Metastases Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Leptomeningeal Metastases Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight